Samuel Han
Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Samuel Han as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:06 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07810309 · Metabolic Impact of Pancreatic Duct DecompressionMayo Clinic · recruiting · Chronic Pancreatitis · principal investigator
- Ph4NCT07285863 · A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy SubjectsMayo Clinic · active not recruiting · Exocrine Pancreatic Insufficiency, Chronic Pancreatitis · principal investigator
- Ph2NCT07171112 · Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic PancreatitisMayo Clinic · withdrawn · Pancreatitis, Chronic, Pancreatitis, Acute, Recurrent Acute Pancreatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:06 UTC. The ranking covers the 200 most relevant of 885 PubMed records, and a shared surname and initials can bring in a namesake. All 885 on PubMed
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.N Engl J Med · 20218,486 citationsRCR 542.4
- 1,056 citationsRCR 68.8
- Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.Lancet Oncol · 2016566 citationsRCR 21.9
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.N Engl J Med · 2021497 citationsRCR 24.5
- 217 citationsRCR 18.3
- 169 citationsRCR 9.1
- Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.J Hepatol · 2016157 citationsRCR 5.4
- Potential of Allogeneic Adipose-Derived Stem Cell-Hydrogel Complex for Treating Diabetic Foot Ulcers.Diabetes · 2019156 citationsRCR 8.7
- A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women.Br J Cancer · 2015146 citationsRCR 4.7
- Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke.N Engl J Med · 2023141 citationsRCR 14.7